AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 MAR 6 - (NewsRx.com & NewsRx.net) -- Antigenics Inc. (AGEN) announced that the U.S. Food and Drug Administration (FDA) has granted the company's personalized cancer vaccine, Oncophage (HSPPC-96), fast track designation for the treatment of metastatic melanoma.
As a fast track product, the FDA will take appropriate actions to expedite the development and review of Oncophage. In October 2001, Oncophage received its first fast track designation - for the treatment of renal cell carcinoma (kidney cancer) - making it the first personalized cancer product to receive fast track designation from the ...